Evotec appoints Joanna Holbrook as chief scientific officer. Evotec stock gains 1.47 percent

Published on 10/21/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month revenue reached EUR 465.0 million on October 13, 2026. Evotec stock costs EUR 2.76 on October 21, 2026, 1.47 percent above Xetra close.

Appointment and earnings timeline

Joanna Holbrook was appointed on October 15, 2026, effective November 1, 2026.
Preliminary nine-month 2026 revenue reached EUR 465.0 million, while adjusted EBITDA was minus EUR 42.8 million.
Evotec stock trades at EUR 2.76 at 10:34 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.47 percent above the Xetra close of October 20, 2026.
RBC kept its EUR 10.00 target and Buy rating on October 14, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Molekülmodell, Pipette und Petrischale auf weißem Grund — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte DE0005664809 visualisiert die Aktie von Evotec SE als Biotech-Investment, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) appointed Joanna Holbrook as chief scientific officer and a member of its management board on October 15, 2026, according to MarketScreener. Evotec stock was trading at EUR 2.76 at Lang & Schwarz on October 21, 2026, 1.47 percent above the Xetra close of October 20, 2026.

Why does the outlook still matter?

Deutsche Boerse reported that Evotec expected preliminary revenue of EUR 465.0 million for the first nine months of 2026 and adjusted EBITDA of minus EUR 42.8 million. The figures were above market expectations, but the company said the difference was largely driven by the timing of consensus estimates.

The company kept its full-year 2026 guidance at EUR 570 million to EUR 610 million of revenue and minus EUR 70 million to minus EUR 105 million of adjusted EBITDA. That contrast is central for investors: the nine-month figures beat expectations, while the company still projects an adjusted operating loss for the full year.

Three dates reshape the timeline

On October 13, 2026, Evotec released preliminary nine-month revenue of EUR 465.0 million and adjusted EBITDA of minus EUR 42.8 million through Deutsche Boerse. On October 14, 2026, RBC kept its Buy rating and EUR 10.00 target, according to MarketScreener. On October 15, 2026, Evotec announced Holbrook's appointment, effective November 1, 2026, as reported by MarketScreener.

What comes next for Evotec?

Holbrook is scheduled to begin on November 1, 2026, while Evotec is scheduled to publish its third-quarter and nine-month results on November 5, 2026, according to the MarketScreener appointment notice and Deutsche Boerse.

Stock quote and valuation

Evotec's market capitalization was EUR 492.6 million on October 21, 2026, while its 52-week range was EUR 2.41 to EUR 7.30. At 10:34 a.m. CEST on October 21, 2026, Evotec stock was trading at EUR 2.76 at Lang & Schwarz, 1.47 percent above the Xetra close of October 20, 2026 at EUR 2.72. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.